At the moment, the only other approved medicine for SMA is Biogen’s blockbuster SMA treatment Spinraza (nusinersen), so it will be interesting to see if Zolgensma’s availability has impacted ...
Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...
GlobalData on MSN6d
Biogen’s higher dose Spinraza under review by US and EU regulatorsBiogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback